title: Results of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastoma.
abstract: BACKGROUND
  Prognosis of relapsed and refractory neuroblastoma is uniformly fatal; new therapeutic approaches are needed.
  
  
  METHODS
  Relapsed and refractory neuroblastoma patients were treated with continuous infusion chemotherapy combined with MIBG.
  
  
  RESULTS
  Over 4 years, 35 heavily pretreated patients were registered, 29 with bone or/and bone marrow metastases. Grade 3 or 4 hematologic toxicity was frequent, without toxic deaths. Sixteen patients responded. The probability of 5-year overall survival was 0.19.
  
  
  CONCLUSIONS
  This approach is feasible and toxicity manageable; it rescued some patients and prolonged their survival. It merits assay in newly diagnosed high-risk neuroblastoma patients.
authors: Unidad de Oncología Pediátrica, Hospital Infantil La Fe, Valencia, Spain.
authors: V
authors: V
authors: Castel
authors: A
authors: A
authors: Cañete
authors: C
authors: C
authors: Melero
authors: T
authors: T
authors: Acha
authors: A
authors: A
authors: Navajas
authors: P
authors: P
authors: García-Miguel
authors: T
authors: T
authors: Contra
authors: J
authors: J
authors: Molina
authors: P
authors: P
authors: Galarón
authors: O
authors: O
authors: Cruz
mesh_terms: D019797:3-Iodobenzylguanidine / Q000627:therapeutic use*; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009447:Neuroblastoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D015996:Survival Rate
chemical_list: D019797:3-Iodobenzylguanidine